Cardiac Medical Devices

Enrollment complete in safety trial of Medtronic's drug-eluting coronary stent system

Published in Drug Week, July 28th, 2006

Medtronic, Inc. (MDT) announced that it has completed patient enrollment in the ENDEAVOR IV clinical study, paving the way for final data evaluation of the Endeavor drug-eluting coronary stent (DES) system and submission to the U.S. Food & Drug Administration (FDA) for U.S. approval.

At the same time, Medtronic also said it has completed enrollment in two other clinical trials: the RESOLUTE study evaluating the company's next generation DES product and the ENDEAVOR-Japan study evaluating the Endeavor stent at 12 clinical sites in Japan.

The ENDEAVOR IV study is part of an extensive clinical program that also includes the ENDEAVOR I, II and III...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-07-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry